Fate Therapeutics Stock News

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati

These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.

Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).

Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT5

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm

SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developme

FATE reports a narrower loss and higher collaboration revenues in the first quarter.

Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, Preside

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks?

Within the last quarter, Fate Therapeutics (NASDAQ: FATE ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 1 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Fate Therapeutics. The company has an average price target of $93.25 with a high of $122.00 and a low of $62.00. Below is a summary of how these 4 analysts rated Fate Therapeutics over … Full story available on Benzinga.com